Home » US FDA Draft Guidance Offers Exceptions for Clinical Trials
US FDA Draft Guidance Offers Exceptions for Clinical Trials
November 17, 2010
There are at least three exceptions that allow sponsors to conduct human clinical trials without an IND submission, the U.S. Food and Drug Administration (FDA) says in a draft guidance designed to clear up confusion and misperceptions about IND exemptions.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor